Understanding the Role of Targets and Pathways in the Treatment of Melanoma
This CME/CE/CPE certified supplement is jointly provided by:
Editorial
A Letter From the Guest Editors
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP
Editorial
A Brighter Future for Patients With Melanoma
Lisa A. Kottschade, APRN, MSN, CNP, and LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP
Review Article
Diagnosis, Evaluation, and Surgical Management of Melanoma
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Christan G. Bartsch, MSHS, PA-C, MPH
Review Article
Harnessing the Immune System in the Treatment of Melanoma
Suzanne McGettigan, MSN, CRNP, AOCN®
Review Article
BRAF/MEK Inhibition in Melanoma: An Update
Lisa A. Kottschade, APRN, MSN, CNP, and Kathleen M. Madden, RN, MSN, FNP-BC, AOCNP®, APHN
Review Article
Mutations Beyond BRAF V600
Mollie Reed, MSN, ACNP-BC
Review Article
Melanomas of Noncutaneous Origin: Diagnosis, Treatment, and Outcomes
Lisa A. Kottschade, APRN, MSN, CNP
Review Article
Supportive Care and Management of Treatment-Related Adverse Effects From Immune Checkpoint Inhibitors and Targeted Therapies in Melanoma
Krista M. Rubin, MS, FNP-BC, and Lisa A. Kottschade, APRN, MSN, CNP
Review Article
Drug-Drug Interactions in Melanoma
LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP
Appendix
Appendix
Compiled by Lisa A. Kottschade, APRN, MSN, CNP